Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Closed 02-18 16:00:00 EST

74.68

-0.18

-0.24%

High74.94	Low74.37	Vol779.56M
Open74.86	D1 Closing74.86	Amplitude0.76%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O14.71B	T/O Rate--	Tradable Shares0.00
P/B7.4028	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":74.6821,"timestamp":1771448399999,"preClose":74.86262,"halted":0,"volume":779563591,"delay":0,"changeRate":-0.002411,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-0.180519,"latestTime":"02-18 16:00:00 EST","open":74.863304,"high":74.93602,"low":74.36978,"amount":14711234212.82469,"amplitude":0.007564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771462800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.4028,"peRate":-184.336219,"turnoverRate":0.023376,"increases":306,"decrements":188,"flats":22,"marketCap":1935152509565.5625,"floatMarketCap":1735491966865.3125},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"2612252094","title":"Compass Pathways Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252094","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612252094?lang=en_us&edition=fundamental","pubTime":"2026-02-19 04:27","pubTimestamp":1771446420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 15:27 ET (20:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2612252964","title":"Class Action Lawsuit Targets REGENXBIO Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252964","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612252964?lang=en_us&edition=fundamental","pubTime":"2026-02-19 04:24","pubTimestamp":1771446249,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Regenxbio Inc. in the U.S. District Court for the District of Maryland on behalf of investors who bought or acquired the company’s securities between Feb. 9, 2022 and Jan. 27, 2026. The complaint alleges the company made misleading statements and omitted material information about the efficacy and safety of its RGX-111 gene therapy program, after the FDA placed the trial on clinical hold following the discovery of an intraventricular CNS tumor in a study participant. Investors have until April 14, 2026 to seek appointment as lead plaintiff.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL1f5Vj2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4112","BK4505","RGNX","SG9999014005.SGD","IE00BGHQF748.EUR","BK4563","IE00BKPKM429.USD","SG9999014039.USD","SG9999014021.USD","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4588","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2612230664","title":"AC Immune Says Recruitment Temporarily Paused in Ongoing Study for Alzheimer's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612230664","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612230664?lang=en_us&edition=fundamental","pubTime":"2026-02-19 03:34","pubTimestamp":1771443242,"startTime":"0","endTime":"0","summary":"AC Immune  said Tuesday it has been notified by Johnson & Johnson  subsidiary Janssen Pharmaceuticals that enrollment has temporarily been paused in the phase 2b study of ACI-35.030/JNJ-2056 on subjects with preclinical Alzheimer's disease.The halt in recruitment is not related to new safety findings, and the trial's pre-specified interim immunogenicity threshold was met, AC Immune said in a regulatory filing.AC Immune said the pause does not impact its current liquidity position. The company added that its existing capital resources are sufficient to fund operations through Q3 of 2027, excluding any potential milestone payments.Price: 2.51, Change: -0.41, Percent Change: -13.92","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0345770308.USD","LU1585245621.USD","LU0114720955.EUR","BK4585","LU2468319806.SGD","LU0985320562.USD","LU1066051225.USD","LU2592432038.USD","LU0203347892.USD","LU1983299246.USD","LU0912757837.SGD","LU1057294990.SGD","SG9999002232.USD","LU0203345920.USD","LU2505996509.AUD","LU2750360641.GBP","LU0234572021.USD","LU1894683264.USD","IE00B19Z3581.USD","IE00B42XCP33.USD","LU1496350502.SGD","LU1506573853.SGD","LU1244550221.USD","LU0795875169.SGD","LU2133065610.SGD","BK4139","BK4592","LU1894683348.USD","LU2505996681.GBP","LU0345770993.USD","LU2471134523.USD","LU0124676726.USD","LU0289739699.SGD","LU1935042991.SGD","ACIU","LU0787776722.HKD","LU1059921491.USD","LU2129689514.USD","IE00BSNM7G36.USD","IE00BLSP4452.SGD","LU1261432733.SGD","LU1718418525.SGD","LU1929549753.HKD","LU1244550494.USD","LU1244550577.SGD","LU2430703095.HKD","LU0640476718.USD","LU1196500208.SGD","LU0345769128.USD","JNJ"],"gpt_icon":0},{"id":"2612423995","title":"ImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2612423995","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612423995?lang=en_us&edition=fundamental","pubTime":"2026-02-19 03:00","pubTimestamp":1771441200,"startTime":"0","endTime":"0","summary":"ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer.The stock climbed 32% to $7.94 on Wednesday. Shares have more than doubled over the past 12 months.The immunotherapy company said Wednesday that the European Commission granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of adult patients with certain types of nonmuscle invasive bladder cancer.With the authorization, Anktiva is now approved in 33 countries spanning four regulator jurisdictions. It was first approved by the U.S. Food and Drug Administration less than two years ago.The authorization comes after patients treated with Anktiva demonstrated a 71% complete response rate in a recent clinical trial.As part of the conditional authorization, ImmunityBio will follow up with trial participants and submit long-term safety and efficacy data to the European Medicines Ag","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"2612633423","title":"Cybin Appoints Michael Cola as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612633423","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612633423?lang=en_us&edition=fundamental","pubTime":"2026-02-19 02:56","pubTimestamp":1771440972,"startTime":"0","endTime":"0","summary":"Cybin Inc., operating as Helus Pharma, announced that Michael Cola has been appointed Chief Executive Officer, effective immediately. The company said Cola brings more than 30 years of experience in neuroscience and specialty pharmaceuticals, including senior leadership roles at Shire, Merck/Astra-Merck, AstraZeneca, and Avalo Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL7y3jYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250843.SGD","LU1003077747.HKD","LU0949170426.SGD","LU0320765489.SGD","LU0310800965.SGD","LU1934455277.USD","LU1880407132.USD","LU1989772923.USD","BK4550","LU0106261372.USD","LU1430594728.SGD","BK4533","BK4588","LU2089284900.SGD","LU1019632923.USD","LU0432979614.USD","LU1929549753.HKD","LU0070302665.USD","LU0965509101.SGD","LU1104425308.USD","LU0345777659.USD","LU0889566641.SGD","SG9999001176.SGD","IE00B1BXHZ80.USD","LU0158827948.USD","LU0889565080.SGD","LU0827474353.SGD","LU1267930573.SGD","LU0949170772.SGD","LU2360032135.SGD","LU1066053197.SGD","LU1941712264.USD","LU1585245621.USD","LU1035773651.USD","LU0265550359.USD","LU1019634622.SGD","LU1066051225.USD","LU2361044865.SGD","LU1699723380.USD","LU0047473722.EUR","LU0011850046.USD","BK4139","IE00B4R5TH58.HKD","IE00BBT3K403.USD","LU0211328371.USD","LU0545039389.USD","LU1941712348.USD","LU1983299246.USD","LU1934455863.HKD","SG9999014567.USD","LU1093756168.USD","LU1051770623.HKD","LU2125154778.USD","LU1170363599.USD","IE00BLSP4239.USD","LU0708994859.HKD","LU0496365809.HKD","LU2112291526.USD","LU0006306889.USD","LU1301847155.USD","IE00BKPKM643.USD","IE00B3T34201.USD","LU0882574055.USD","LU0963555726.SGD","LU2361044949.HKD","LU1003076772.USD","LU1084165304.USD","LU1267930490.SGD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LU1917777945.USD","LU1989772840.SGD","IE00BJJMRZ35.SGD","LU0077335932.USD","LU0980610538.SGD","SG9999014559.SGD","IE00BFTCPJ56.SGD","LU1571399168.USD","IE0002141913.USD","LU1162221912.USD","LU0997586432.USD","LU0289739699.SGD","LU0310799852.SGD","LU0203347892.USD","LU0965508806.USD","LU0029864427.USD","LU0130517989.USD","LU2461242641.AUD","LU0211326755.USD","LU0969580561.USD","LU0477156953.USD","LU0320765646.SGD","LU1037948541.HKD","SG9999014542.SGD","LU1201861249.SGD","LU0640478417.SGD","LU0114720955.EUR","IE00BLSP4452.SGD","LU1116320901.HKD","LU1061106388.HKD","IE00BN8TJ469.HKD","LU0784385840.USD","SG9999001440.SGD","LU0122379950.USD","LU0128525689.USD","LU1057294990.SGD","LU0208291251.USD","LU1481600234.SGD","LU2091194634.USD","SG9999013999.USD","BK4559","LU0345777147.USD","LU0920840948.USD","LU1153584641.USD","LU1267930227.SGD","LU1496350502.SGD","LU0265550946.USD","LU1069347547.HKD","LU0823399737.USD","BK4585","LU0972486137.USD","IE00BJT1NW94.SGD","LU1880407215.USD","LU1116320737.USD","SG9999014575.USD","LU1015430645.USD","LU0553294199.USD","LU0957799991.USD","BK5011","LU0784384876.USD","03165","LU0857590862.USD","LU2089283258.USD","LU2324357040.USD","LU2279689827.SGD","LU1037948897.HKD","LU1934455194.USD","LU2468319806.SGD","LU0128525929.USD","LU2089984988.USD","LU0648001328.SGD","BK4534","LU2023250504.SGD","SG9999015341.SGD","SG9999002232.USD","LU0985320562.USD","LU0661504455.SGD","LU1267930813.SGD","LU2114397693.USD","LU0211326839.USD","LU0920783379.SGD","LU1119994496.HKD","LU0047473722.SGD","LU0738911758.USD","LU0238689110.USD","LU1291159041.SGD","LU0499090636.EUR","IE0009355771.USD","LU0058720904.USD","LU0052756011.USD","LU0861579265.USD","LU1323610961.USD","LU1974910355.USD","IE000M9KFDE8.USD","LU0965509010.AUD","LU1261432733.SGD","LU0792757196.USD","LU0575583348.USD","LU1093756325.SGD","LU1814569148.SGD","LU2539964713.USD","LU1989771016.USD","SG9999001176.USD","SG9999002224.SGD","LU0976567544.SGD","LU1064927863.SGD","LU1481599808.USD","LU1487256676.USD","LU0526926950.USD","LU2293690082.USD","BK4007","LU0964806797.USD","LU1496350171.SGD","LU0211331839.USD","LU2293690249.USD","LU0310800379.SGD","LU2361045086.USD","SGXZ57979304.SGD","LU0960981461.USD","LU0098860793.USD","LU1066051811.HKD","LU2023251221.USD","LU0211327993.USD","LU0757432116.USD","LU1078025761.USD","LU0171293334.USD","LU0234572021.USD","BK4516","LU0784383803.USD","LU0130102774.USD","LU0203345920.USD","LU1153585028.USD","LU2108987350.USD","LU2125154935.USD","SG9999015358.SGD","LU2106854487.HKD","LU0887340254.USD","LU0557290698.USD","LU1023059063.AUD","LU0965509283.SGD","LU0823416689.USD","LU1066051498.USD","LU0266013472.USD","LU0784385170.HKD","LU2133065610.SGD","IE0034235188.USD"],"gpt_icon":0},{"id":"2612423560","title":"Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2612423560","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612423560?lang=en_us&edition=fundamental","pubTime":"2026-02-19 02:51","pubTimestamp":1771440660,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement.The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks.Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others.Faeth is developing drugs that target tumor metabolism and signaling.On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time.Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNSE"],"gpt_icon":0},{"id":"2612428023","title":"BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Fresh Del Monte Produce, Crescent Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428023?lang=en_us&edition=fundamental","pubTime":"2026-02-19 02:38","pubTimestamp":1771439926,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Fresh Del Monte Produce, Crescent BiopharmaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morni","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nL6N3ZE0K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481011911.USD","LU1691799644.USD","IE00B3SWFQ91.USD","LU0868494617.USD","IE00B7SZLL34.SGD","LU0274383776.USD","BK4211","LU0302445910.USD","LU1035773651.USD","LU1814569148.SGD","LU1267930573.SGD","LU1951198990.SGD","LU2063271972.USD","BK4501","LU1571399168.USD","SG9999014914.USD","3NVD.UK","BK4585","BK4587","BK4209","LU1232071149.USD","LU0266013472.USD","LU0170899867.USD","LU1839511570.USD","LU2087621335.USD","LU1934455277.USD","LU2756315318.SGD","LU2860962120.EUR","LU1670628061.USD","BK4101","LU2308191902.HKD","LU2264538146.SGD","IE00B775H168.HKD","LU0157215616.USD","BK4023","LU0792757196.USD","IE0004091025.USD","LU0158827948.USD","LU1868836757.USD","IE00BZ1G4Q59.USD","LU0278409577.USD","SG9999015341.SGD","IE00BMPRXQ63.HKD","LU0964807845.USD","LU0496367417.USD","LU0312595415.SGD","LU1852331112.SGD","LU0689472784.USD","LU0208291251.USD","SG9999002224.SGD","LU0772969993.USD","LU1868837136.USD","BK4503","BK4549","LU2746668974.SGD","LU2417539215.USD","IE00BQXX3C00.GBP","LU0466842654.USD","NVDX","LU2458330243.SGD","LU1699723380.USD","LU0505663152.USD","LU2048586759.USD","LU1267930813.SGD","LU0260871552.USD","LU2361044865.SGD","IE00BJJMRX11.SGD","LU0107464264.USD","LU1791710582.SGD","SG9999014906.USD","LU1366192091.USD","LU0823434740.USD","LU2168564065.EUR","SG9999004303.SGD","IE00BWXC8680.SGD","LU0061475181.USD","LU0345780281.USD","LU1633808545.USD","LU2271345857.HKD","LU1116320737.USD","LU0310799852.SGD","LU2111349929.HKD","LU1585245621.USD","LU1721428933.USD","BK4612","LU0310800379.SGD","BK4159","IE0004445015.USD","GB00BDT5M118.USD","LU1923623000.USD","LU2213496289.HKD","LU2360032135.SGD","LU1242518931.SGD","IE00B3S45H60.SGD","BK4568","IE00B19Z8X17.USD","LU0308772762.SGD","LU1093756168.USD","LU1815333072.USD","LU0965508806.USD","LU2324357040.USD","LU2133065610.SGD","LU1119994496.HKD","LU1861215975.USD","BK4598","LU0314104364.USD","BK4515","IE0034235188.USD","LU0345780521.USD","LU2357305700.SGD","LU0612318971.USD","LU0788108826.HKD","LU2083900584.USD","LU2097344431.USD","LU2168563687.JPY","LU2294711713.HKD","LU1914381329.SGD","IE00B775SV38.USD","SG9999014575.USD","LU2211815571.USD","IE0003U64NQ7.SGD","LU0348723411.USD","LU2125909593.SGD","NVDU","IE0004445239.USD","IE00BJLML261.HKD","LU0476273544.USD","LU0889566641.SGD","IE0034235303.USD","BK4150","LU2764262908.HKD","LU0965509283.SGD","LU1599440770.SGD","LU0742537680.HKD","LU1935042215.USD","LU0823421416.USD","LU0528227936.USD","LU1169590202.USD","IE00B2PGVK34.USD","LU0689626769.HKD","LU1496350502.SGD","LU2065170008.USD","LU0788109477.HKD","BK4581","LU1261432733.SGD","NVDS.UK","LU1863844749.USD","BK4550","LU0256331488.USD","LU0511384066.AUD","LU1988902786.USD","LU0069063385.USD","LU1267930730.SGD","IE000KEQY171.SGD","LU1670711123.USD","LU2463028550.USD","SG9999001424.SGD","LU2023250843.SGD","IE0005OL40V9.USD","BK4231","LU2265009873.SGD","LU0347712357.USD","LU2089283258.USD","SGXZ23171101.USD","BK4170","LU0127658192.USD","LU1223083913.SGD","LU1804176565.USD","LU0820561909.HKD","LU1989772923.USD","LU2247934214.USD","LU2237438978.USD","LU1429558221.USD","IE00B1BXHZ80.USD","IE00BHPRN162.USD","BK4210","LU0979878070.USD","LU2498475776.HKD","LU0276348264.USD","LU1069347547.HKD","SG9999017495.SGD","LU2089985449.USD","LU0498741114.HKD","LU2065171311.SGD","LU0477156797.USD","LU1674673428.USD","LU2168564495.EUR","IE00B3CCJ633.GBP","LU0345768740.USD","LU1023059493.AUD","LU0265550946.USD","LU2106854487.HKD","LU1670710588.SGD","LU2361044949.HKD","LU1066051225.USD","LU1242518857.USD","LU1803068623.USD","LU1951200564.SGD","LU2023250504.SGD","LU0225283273.USD","IE00BKPKM429.USD","LU1430594728.SGD","LU0965509101.SGD","LU1074936037.SGD","HK0000306701.USD","LU0345780950.USD","LU0211328371.USD","BK4097","LU0130103400.USD","LU0256863811.USD","LU0234570918.USD","LU2236285917.USD","LU1778281490.HKD","LU1623119135.USD","BK4595","LU0353189763.USD","LU0882574139.USD","LU1989772840.SGD","LU0957791311.USD","BK4213","LU2290526834.HKD","LU1316542783.SGD","LU0289739343.SGD","LU1366333091.USD","LU0672654240.SGD","LU1861214812.USD","BK4082","LU0648000940.SGD","LU0265550359.USD","BK4160","LU0612318385.USD","IE00BMPRXN33.USD","LU1978683503.SGD","LU1894683348.USD","LU1935043536.SGD","BK4527","LU2360107168.USD","LU0094547139.USD","SG9999015978.USD","LU2473716301.USD","DIPS","LU0128525929.USD","HK0000320223.HKD","LU2097344357.USD","BK4543","LU0234572021.USD","IE00BDRTCR15.USD","SG9999014898.SGD","FDP","LU0081259029.USD","LU2210149790.SGD","LU0079474960.USD","IE00BYXW3230.USD","LU0203201768.USD","LU1430597077.USD","CBIO","IE00BFSS7M15.SGD","LU2471134879.HKD","IE00BK4W5L77.USD","LU1244550221.USD","LU0889565080.SGD","LU2462611646.USD","BK4579","LU0158827781.USD","LU1509826696.USD","IE00BDCRKT87.USD","IE00B894F039.SGD","HK0000306685.HKD","LU0494093205.USD","LU0154236417.USD","SGXZ31699556.SGD","LU1821325948.USD","BK4152","LU1935042991.SGD","LU1670711040.USD","LU1868837300.USD","LU2087625088.SGD","LU2413666699.HKD","LU0708994859.HKD","BK4015","LU2487616109.SGD","SG9999018865.SGD","LU0345781412.USD","LU0965509010.AUD","LU1803068979.SGD","LU1992135399.USD","BK4147","LU1267930490.SGD","LU2272731865.HKD","LU2322448957.HKD","LU0731783048.USD","IE00B19Z9505.USD","IE00BJJMRY28.SGD","LU1868836591.USD","LU2250418816.HKD","LU1323610961.USD","LU0368265764.SGD","LU0238689110.USD","LU2191332357.HKD","IE00BK4W5M84.HKD","LU0823414478.USD","LU2462157665.USD","LU0057025933.USD","IE00B19Z3B42.SGD","LU1280957306.USD","SG9999014880.SGD","LU0203202063.USD","LU2168564149.EUR","LU0072462426.USD","LU1235295455.SGD","BK4534","BK4566","LU0211327993.USD","LU0300736492.USD","LU0630314457.HKD","LU2237443549.SGD","IE00BJTD4N35.SGD","LU1983299162.USD","LU0820561818.USD","LU0345769128.USD","IE00BKDWB100.SGD","LU0330918003.SGD","LU2237443622.USD","2NVD.UK","LU2360106780.USD","LU0868494708.USD","LU0557290698.USD","LU1551013342.USD","NVDW","LU1861127337.USD","SG9999014542.SGD","SNVD.UK","BK4157","LU0719512351.SGD","LU0029864427.USD","LU1712237335.SGD","LU0320765059.SGD","IE0004086264.USD","SGXZ51526630.SGD","BK4512","BK4532","LU0788109121.HKD","LU2125154778.USD","LU1066053197.SGD","LU0124384867.USD","LU2092937148.SGD","IE00BZ9MQY76.HKD","LU2242649171.HKD","LU2413666426.HKD","LU1935042488.USD","BK4608","LU1992135472.HKD","LU0640476718.USD","SG9999015358.SGD","IE0009356076.USD","NVDS","LU0106261372.USD","LU2458330169.SGD","LU2077746001.SGD","IE00BMPRXR70.SGD","LU1989764664.SGD","LU2381873111.SGD","BK4560","LU0096362180.USD","LU0654597011.USD","LU0342679015.USD","IE00BN29S564.USD","LU0345768153.USD","LU0300736062.USD","LU1934455194.USD","LU1035775433.USD","LU1145028129.USD","LU2764263203.CNY","LU1244550494.USD","LU0345769631.USD","LU2168564222.USD","IE00B19Z8W00.USD","LU0266512127.USD","LU2028103732.USD","BK4189","LU0823414551.USD","LU1642822529.SGD","LU0985320562.USD","LU0077335932.USD","LU0353189680.USD","IE0002270589.USD","HK0000320264.USD","LU2275660780.HKD","LU2420271590.USD","LU2543165471.USD","SGXZ99366536.SGD","SG9999002232.USD","BK4605","LU2125909247.SGD","LU2065731478.USD","LU2461242641.AUD","LU2125154935.USD","LU2108987350.USD","IE00BD6J9T35.USD","LU0320765489.SGD","LU2237443978.SGD","LU2237957902.USD","BK4567","LU0054578231.USD","LU0456854461.SGD","BK4548","LU2298322129.HKD","IE00B3M56506.USD","LU2065169927.USD","IE0001KFT4U8.USD","LU2237957811.SGD","NVDD","LU1481011671.HKD","LU0138981039.USD","BK4554","LU0109392836.USD","LU0251132253.USD","BK4107","LU1974910355.USD","LU2896262040.SGD","NVII","IE00B19Z9Z06.USD","BK4141","LU0861579265.USD","LU0256863902.USD","LU2491050071.SGD","LU0786609619.USD","IE00BJTD4V19.USD","BK4080","LU0390134368.USD","IE0009G5SDU7.USD","LU1169589451.USD","LU0444973449.USD","LU2471134796.USD","LU1720051017.SGD","LU2552382215.SGD","LU0354030438.USD","BK4081","LU0198837287.USD","LU1496350171.SGD","LU1548497426.USD","BK4166","LU2054465674.USD","LU2505996509.AUD","LU2249611893.SGD","IE00B4JS1V06.HKD","LU0006306889.USD","LU0187121727.USD","LU1037948541.HKD","LU0082616367.USD","LU0787776722.HKD","LU0708995401.HKD","BK4516","LU1718418525.SGD","IE00B7KXQ091.USD","LU1883866441.USD","IE00BKVL7J92.USD","LU1935043023.USD","LU0124676726.USD","LU2361045086.USD","LU1917777945.USD","LU2430703095.HKD","LU2433249047.HKD","BK4570","BK4533","LU0444971666.USD","LU0130518102.USD","IE000ITXATA3.USD","LU0175139822.USD","BK4592","LU1127390331.HKD","LU0354030511.USD","LU2272731600.USD","BK4111","IE00B1XK9C88.USD","NVDQ","SG9999015952.SGD","LU1894683264.USD","LU0943347566.SGD","LU0728928796.USD","LU2092627202.USD","LU2471134952.CNY","IE00B19Z3581.USD","LU2355687059.USD","SG9999014567.USD","LU0731783394.SGD","NVD3.UK","LU0055631609.USD","LU0056508442.USD","LU0061474960.USD","LU1435385759.SGD","LU1069344957.HKD","LU0266512473.USD","LU1223082196.USD","LU2756315664.SGD","LU0823421333.USD","BK4614","LU2430703251.USD","LU2720916845.USD","LU2764263039.SGD","LU2456880835.USD","LU1863844665.USD","LU0472753341.HKD","LU0942090050.USD","LU2360107325.USD","LU2023250330.USD","BK4519","LU1670627923.USD","LU0070217475.USD","LU0642271901.SGD","LU0075056555.USD","LU0109391861.USD","LU0889565833.HKD","SG9999000418.SGD","LU1934455863.HKD","BK4561","BK4139","LU2746668461.USD","LU2452424414.USD","SG9999001143.SGD","LU2505996681.GBP","LU1868836914.USD","IE00BQXX3D17.EUR","LU0316494557.USD","IE00B4YYXB79.USD","IE00B19Z9P08.USD","IE00B5949003.HKD","SG9999018857.SGD","LU0345770308.USD","LU0215105999.USD","LU2272731782.SGD","LU2125909916.SGD","LU1674673691.USD","LU1983260115.SGD","LU1551013425.SGD","LU2065171402.SGD","NVD2.UK","LU0267386448.USD","LU2491049909.HKD","LU2552382058.USD","LU1223082519.USD","LU2552382132.HKD","LU0683600562.USD","LU2506951792.HKD","LU1037948897.HKD","LU0070302665.USD","BK4179","IE00BQXX3F31.USD","LU2430703178.SGD","LU2210150020.SGD","NVIW.SI","NVD","BK4600","LU2326559502.SGD","HK0000914686.HKD","IE000YTNTUN2.SGD","BK4551","LU1861220033.SGD","IE00BFSS8Q28.SGD","LU0210536198.USD","LU0323591593.USD","NVDG","LU0820562030.AUD","LU1244550577.SGD","LU0724618433.USD","LU2023251221.USD","LU0957808578.USD","LU2237443382.USD","LU1923622291.USD","LU2125909759.SGD","BK4138","IE0034235295.USD","LU1084165304.USD","BK4529","BK4588","IE00BZ199S13.USD","LU1720051108.HKD","LU2750360997.AUD","SGXZ81514606.USD","LU1670710661.SGD","LU0210528500.USD","HK0000914660.USD","LU0498741890.SGD","LU1116320901.HKD","LU1153585028.USD","LU2471134523.USD","SG9999002521.SGD","LU0724617625.USD","LU0823434583.USD","LU1923622614.USD","LU0289961442.SGD","BK4564","SG9999015986.USD","LU1989764748.USD","FCX","LU0011850046.USD","LU1066051811.HKD","SG9999014559.SGD","LU1093756325.SGD","LU1629891620.HKD","LU2357125470.USD","LU0061474705.USD","LU1066051498.USD","LU1791710400.SGD","LU2931357623.SGD","LU3187612489.SGD","LU2491050154.USD","LU0724618789.USD","LU2750360641.GBP","LU2602419157.SGD","LU0097036916.USD","LU0289960550.SGD","LU0080751232.USD","LU2242650005.HKD","SG9999011175.SGD","IE00BGHQF417.EUR","SG9999003800.SGD","LU0096364046.USD","LU1861219969.SGD","LU2089284900.SGD","LU2592432038.USD","SG9999015945.SGD","BK4187","NVDY","LU1064131342.USD","LU0210533765.USD","IE000W1ABFV2.USD","LU1815336760.USD","BK4017","LU1201861165.SGD","LU2286300806.USD","LU2095319765.USD","LU0048584097.USD","LU2403377893.USD","LU0417517546.SGD","LU0345770993.USD","LU2322448791.USD","LU2244417387.USD","LU0053666078.USD"],"gpt_icon":1},{"id":"2612428251","title":"Here’s Why Tempus AI Stock (TEM) Is Rallying Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428251?lang=en_us&edition=fundamental","pubTime":"2026-02-19 02:06","pubTimestamp":1771437971,"startTime":"0","endTime":"0","summary":"Tempus AI ($TEM) announced a major milestone with the launch of its new pan-cancer HRD‑RNA algorithm. This tool helps clinicians identify patients ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/heres-why-tempus-ai-stock-tem-is-rallying-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/heres-why-tempus-ai-stock-tem-is-rallying-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4121","LU1861559042.SGD","IE0009354923.USD","BK4505","BK4587","LU1861558580.USD","BK4585","RNA","AI","BK4543","BK4588","BK4613","BK4528","TEM","BK4023","BK4551","BK4611"],"gpt_icon":0},{"id":"2612428695","title":"Compass Pathways Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428695?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:57","pubTimestamp":1771437420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 12:57 ET (17:57 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2612042889","title":"NewAmsterdam Pharma Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2612042889","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612042889?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:44","pubTimestamp":1771436640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 12:44 ET (17:44 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2612428500","title":"Enlivex Therapeutics management to meet virtually with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428500","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428500?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:40","pubTimestamp":1771436432,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on February 23-26 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-management-to-meet-virtually-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-management-to-meet-virtually-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2612440091","title":"Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Moleculin Biotech (MBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612440091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612440091?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:30","pubTimestamp":1771435811,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research Report)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-newamsterdam-pharma-company-nams-and-moleculin-biotech-mbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-newamsterdam-pharma-company-nams-and-moleculin-biotech-mbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4581","BK4585","BK4139","BK4137","LABU","BK4588","MBRX","XLV","LU0128526141.USD","XBI","NAMS","LU0029874061.USD"],"gpt_icon":0},{"id":"2612428725","title":"Ultragenyx Lawsuits Add Legal Overhang To Setrusumab Setback And 2027 Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428725","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428725?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:29","pubTimestamp":1771435753,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical (NasdaqGS:RARE) faces multiple securities class action lawsuits tied to its setrusumab program.\nComplaints follow disclosures that the Phase III Orbit and Cosmic studies did not meet their primary endpoints.\nPlaintiffs allege management made misleading statements about setrusumab efficacy and risks, citing sharp investor losses after the trial updates.\n\nFor investors watching RARE, the legal challenges come after a tough share price stretch, with the stock at $20.18...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-lawsuits-add-legal-overhang-to-setrusumab-setback","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-lawsuits-add-legal-overhang-to-setrusumab-setback","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2612428735","title":"A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Strength And Mixed Analyst Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428735","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428735?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:28","pubTimestamp":1771435684,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) has drawn fresh attention after recent trading left the stock near US$81, with a one day gain of about 1% alongside mixed short term moves over the past week and month.\nSee our latest analysis for Ionis Pharmaceuticals.\nAlthough the 1 day share price return of 0.94% and recent 7 day weakness suggest some hesitation, Ionis Pharmaceuticals still carries positive momentum, with a 30 day share price return of 6.59% and a 1 year total shareholder return of 154.65%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-recent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/a-look-at-ionis-pharmaceuticals-ions-valuation-after-recent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2612167440","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: ImmunityBio (IBRX) and Bausch + Lomb Corporation (BLCO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612167440","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612167440?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:10","pubTimestamp":1771434618,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ImmunityBio (IBRX – Research Report) and Bausch + ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-immunitybio-ibrx-and-bausch-lomb-corporation-blco-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-immunitybio-ibrx-and-bausch-lomb-corporation-blco-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","BK4581","XLV","IBRX","BK4139","BK4585","BLCO","LU0029874061.USD","LU0128526141.USD","LABU","BK4588","HCSG","BK4198"],"gpt_icon":0},{"id":"2612440859","title":"BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts","url":"https://stock-news.laohu8.com/highlight/detail?id=2612440859","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612440859?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:00","pubTimestamp":1771434027,"startTime":"0","endTime":"0","summary":"BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts** Shares of drugmaker Crescent Biopharma CBIO.O rise 4% to $9.68  ** Co says it has begun a global earlystage trial of CR001 for advanced solid tumors** CR001 is an experimental cancer drug designed to help the immune system attack tumors and block blood supply, CBIO says** Co says study will test safety and how the drug moves and acts in the body before checking for early signs of tumor shrinkage** Trial to enroll up to 290 patients across the U.S., Europe and Asia Pacific; initial data expected in early 2027, CBIO says** Co says it has granted China-based cancerdrug developer Sichuan Kelun-Biotech exclusive rights to develop and sell the drug in Greater China** Shares down ~52% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nL4N3ZE19W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK0060","06990","LU1979443071.USD","LU1064131003.USD","LU2148510915.USD","BK4139","LU0196878994.USD","LU1934453819.USD","LU1064130708.USD","BK0239","BK1161","002422"],"gpt_icon":0},{"id":"2612244011","title":"LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2612244011","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612244011?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:00","pubTimestamp":1771434016,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, February 18th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-appoints-sidney-braun-as-ceo-of-liora-technologies-europe-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-appoints-sidney-braun-as-ceo-of-liora-technologies-europe-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QYLG","SQQQ","QID","QYLD","GPIQ","LIXT","QQQE","JEPQ",".IXIC","BK4139","MNQmain","USAW.SI","QQQY","NQmain","TQQQ","PSQ","QQQJ","USJW.SI","QLD","NVIW.SI","TSYW.SI"],"gpt_icon":0},{"id":"2612744711","title":"CureVac’s CVGBM Brain Cancer Vaccine Trial Reaches Completion: What It Means for CVAC Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2612744711","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612744711?lang=en_us&edition=fundamental","pubTime":"2026-02-19 00:30","pubTimestamp":1771432240,"startTime":"0","endTime":"0","summary":"Curevac N.V. ($CVAC) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1 Dose-Finding Study to Evaluate Safety and To...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curevacs-cvgbm-brain-cancer-vaccine-trial-reaches-completion-what-it-means-for-cvac-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curevacs-cvgbm-brain-cancer-vaccine-trial-reaches-completion-what-it-means-for-cvac-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","BK4548","CVAC","ISBC","BK4551"],"gpt_icon":0},{"id":"2612144715","title":"Unicorn AIM VCT Cancels 2.5 Million Shares in Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2612144715","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612144715?lang=en_us&edition=fundamental","pubTime":"2026-02-19 00:27","pubTimestamp":1771432045,"startTime":"0","endTime":"0","summary":"Unicorn AIM VCT ( ($GB:UAV) ) has provided an announcement. Unicorn AIM VCT PLC has executed a share buyback, purchasing 2,515,831 of its own ordin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/unicorn-aim-vct-cancels-2-5-million-shares-in-buyback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/unicorn-aim-vct-cancels-2-5-million-shares-in-buyback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","BK4139","AIM"],"gpt_icon":0},{"id":"2612442014","title":"Genmab Shares Fall as Costs Weigh on Earnings -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2612442014","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612442014?lang=en_us&edition=fundamental","pubTime":"2026-02-19 00:19","pubTimestamp":1771431540,"startTime":"0","endTime":"0","summary":"Copyright (c) 2026 Dow Jones & Company, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB","BK4139"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0127},{"period":"3month","weight":0.0305},{"period":"6month","weight":0.0744},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}